65,437 trials
Cancer · Cancer Pain
Primary: Proportion of Non-Responder (NR) Participants — 14; 18; 14; 11 participants
Hepatitis C, Chronic
Primary: SVR12: Plasma HCV RNA Level Less Than 25 IU/mL at 12 Weeks After End of Treatment (EOT) — 61.1; 52.9 Percentage of participants
Head and Neck Cancer
Primary: To Determine the Overall Response Rate (CR+PR) — 8 participants
Non-small Cell Lung Cancer
Primary: Overall Survival — 25.6; 22.3 months — p=0.1566
Lung Cancer
Primary: To Measure the Number of Cycles — 20; 3 participants
Head and Neck · Squamous Cell Cancer
Primary: Number of Patients With Overall Objective Response — 4; 2; 12; 5 participants
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration — 895; 986 ng/mL
Psoriasis Vulgaris
Primary: Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity (HI) Group) as Compared to the Control Area at End of…
Lung Neoplasms · Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, and TEAEs With Cancer and Leukemia Group B (CALGB) Toxicity…
Critical Limb Ischemia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Major Limb Amputation Free Survival Post BMMNC Administration — 14; 3; 2; 2 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.98; -1.00 percentage of glycosylated haemoglobin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.56; -1.22 percentage of glycosylated haemoglobin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.79; -0.70 percentage of glycosylated haemoglobin
Thoracic Aorta · Thoracic Injuries · Blunt Injuries
Primary: All-cause Mortality — 1 participants
Small Cell Lung Cancer
Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10